McKesson News

McKesson Declares Quarterly Dividend July 26, 2017

Read More

McKesson Announces Preliminary Voting Results from 2017 Annual Meeting of Stockholders

Read More

NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting

Read More

McKesson Corporation Fiscal 2018 First Quarter Conference Call Scheduled for July 27, 2017

Read More

McKesson Pharmacy Systems Unveils Key Enhancements for Its Pharmacy Management Product Lines

Read More

Mac Prescription Shop Health Mart Receives McKesson’s 2017 Pharmacy of the Year Award

Read More

McKesson Specialty Health Completes Acquisition of intraFUSION

Read More

Biologics, Inc. Earns Prestigious URAC Accreditation for Specialty Pharmacy

Read More

McKesson Reaffirms Fiscal 2018 Guidance

Read More

The US Oncology Network Hosts Second Annual Boot Camp Focusing on New Value-Based Care and Payment Models

Read More

McKesson Specialty Health Expands Provider Offerings with Acquisition of intraFUSION

Read More

McKesson Corporation to Webcast Investor Day

Read More

McKesson Specialty Health and The US Oncology Network Expand Agreement with The National Comprehensive Cancer Network, Adding New Disease States to Value Pathways

Read More

Arizona Oncology Opens State-of-the-Art Cancer Treatment Center at ASU Research Park

Read More

Virginia Cancer Specialists Opens New Research Facility for Phase I Clinical Trials, Leading the Region in Advanced Cancer Research

Read More

McKesson Specialty Health Approved as Qualified Clinical Data Registry by CMS

Read More

Community Oncologists from The US Oncology Network and US Oncology Research Share Meaningful Research and Visionary Thinking During American Society of Clinical Oncology Annual Meeting

Read More

McKesson Corporation to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

Read More

McKesson Declares Quarterly Dividend May 24, 2017

Read More

Biologics’ Patient Access Services Team Procures more than $44 Million in Co-pay Assistance for Cancer Patients in 2016

Read More

IMFINZI (durvalumab) Approved for Previously Treated Patients with Advanced Bladder Cancer, available immediately at Biologics, Inc.

Read More

McKesson Reports Fiscal 2017 Fourth-Quarter and Full-Year Results

Read More

McKesson Specialty Health Selected by TESARO to provide ZEJULA (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

Read More

ALUNBRIG (brigatinib) Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.

Read More

RYDAPT (midostaurin) Approved for the Treatment of FLT3-Mutated Acute Myeloid Leukemia, available for order at Biologics, Inc.

Read More

Thought Leaders from McKesson Specialty Health and The US Oncology Network Are Key Presenters at the 2017 Community Oncology Conference

Read More

US Oncology Research Enrolls 2,900 Patients in Leading-Edge Clinical Trials in Twelve Months

Read More

Biologics, Inc. Selected by TESARO as a Specialty Pharmacy Provider for ZEJULA (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

Read More

McKesson Corporation Fiscal 2017 Fourth Quarter Conference Call Scheduled for May 18, 2017

Read More

McKesson Response to Arkansas Department of Correction’s Planned Executions

Read More